【中泰医药】脑机动态定期更新 近期部分重要进展： 1、赵继宗院士牵头制定的《植入式脑机接口临床应用路径管理中国专家共识（2026 版）》正式发布，推动 iBCI 临床转化科学、安全、有序发展； 2、民政部印发《关于进一步推进民政科技创新的指导意见》，《意见》要求广泛应用人形机器人、脑机接口、人 工智能等前沿技术，开展失能失智预防和抗衰老、生活照料和康复护理、精神慰藉和社会参与促进、安全风险监 测和紧急救援、老年宜居 仅需3分钟就能迅速打开血脑屏障，与血脑屏障未开放的脑组织相比，药物浓度可以平均提高8倍，并且在治疗后6 小时关闭血脑屏障，疗效和安全性均优于国际相关报道； 7、Ybrain招募三星电子和VUNO前高管，推广基于tDCS和脑电图技术的非口服抗抑郁药、打造AI心理健康生态系 统； 8、韩国数字医疗企业Neofect宣布与韩德联合财团合作，共同推进脑机接口商业化，项目将耗时36个月（2025.9- 2028.8）研发基于脑神经控制的脑卒中患者上肢辅助与康复机器人系统。 【中泰医药】脑机动态定期更新 近期部分重要进展： 1、赵继宗院士牵头制定的《植入式脑机接口临床应用路径管理中国专家共识（2026 版）》 ...

脑机接口硬件设备主要包括脑电采集设备、脑机接口芯片，以及电源、采集器、同步器、刺激器、解码 器等设备零部件。其中，脑机接口硬件设备最为核心的便是用于脑电信号采集或神经反馈的脑电采集设 备(即电极)，以及用于脑电信号处理的脑机接口芯片。脑机接口芯片分为侵入式和非侵入式两大类，其 中侵入式脑机接口芯片要求远高于非侵入式。在侵入式脑机接口中，芯片的主要功能包括数据读出和信 号激励，此外为了保证方便和外界沟通还需要使用无线传输。 | 数据或出 | 数据读出主要是指脑机接口从脑部该取特定区域的信号,并且在芯片上做一系列初步处理,包括滚波 | | --- | --- | | | 等。具体多少信号处理在芯片上做,多少传输到片外完成则取决于整个芯片的设计考量。例如,对于 | | | 一些需要做快速反应的脑机接口芯片(例如检测颠縮并快速介入),则需要把尽可能多的处理在芯片 | | | 上实现,以满足延迟的需求。此外,通常经过芯片处理的信号比起原始信号的数据量会小,因此脑机 | | | 接口片上处理部分和无线数据传输部分是一对重要的权衡对象;片上处理越简单,则相关电路逻辑面 | | | 积和功耗越小,但是需要无线传输的数据量就越 ...

Core Insights - Public fund institutions have significantly increased their research activities in January, focusing on AI computing power, high-end medical technology, and new energy as the three core investment themes [1][3][5] Group 1: Research Activity - A total of 156 public fund institutions participated in A-share research in January, covering 486 stocks across 17 industries, with a total of 3,992 research instances [1] - Leading institutions such as Bosera Fund, Huaxia Fund, and Penghua Fund conducted the most research, with Bosera Fund leading at 116 instances [2] - The most researched stocks included Zhongji Xuchuang in the communications sector with 61 instances, followed by Aipeng Medical and Xiangyu Medical in the medical sector with 57 and 47 instances respectively [2] Group 2: Industry Focus - The electronics industry was the most researched, with 603 instances covering 71 stocks, followed by the machinery equipment industry with 591 instances covering 67 stocks [2][3] - Other industries such as medical biology, electric equipment, and basic chemicals also saw significant research activity, each exceeding 276 instances [3] Group 3: Emerging Trends - Brain-computer interfaces have emerged as a key focus within the high-end medical sector, driven by technological breakthroughs and commercial progress [4] - Companies like Aipeng Medical and Meihai Medical are actively engaging in brain-computer interface developments, with Aipeng Medical discussing advancements in brainwave technology [4] - The year 2026 is anticipated to be pivotal for the commercialization of invasive brain-computer interfaces, with several companies already in clinical stages [4]

Core Viewpoint - In January, the global asset allocation logic shifted from valuation recovery to profit-driven, with A-shares continuing an upward trend supported by policies, funding, and valuation [1][2]. Group 1: A-share Market Performance - The A-share market showed a steady upward trend in January, with the Shanghai Composite Index rising by 3.76%, the ChiNext Index by 4.47%, and the Shenzhen Index by 5.03% by the end of January [2]. - The non-ferrous metals sector led the gains with a 22.59% increase, followed by media, oil and petrochemicals, construction materials, and basic chemicals with respective increases of 17.94%, 16.31%, 13.31%, and 12.72% [2]. Group 2: Fund Performance - Public FOFs (funds of funds) performed well, with some products achieving monthly returns exceeding 30%. For instance, the Guotai Industry Rotation A fund had a monthly return of 30.31%, while the Guotai Preferred Navigation fund reached 37.12% [3][5]. - A total of 35 FOFs had monthly performance exceeding 10%, with 4 funds surpassing 20% [3]. Group 3: Market Trends and Predictions - Analysts noted that the core drivers of asset performance in January were cross-year capital reallocation and sentiment recovery, with expectations of a "spring excitement" in the stock market in the first quarter [3][7]. - The transition from valuation-driven to profit-driven narratives in global asset allocation is expected to continue, with a focus on sectors showing clear performance improvements, particularly in technology and cyclical industries [7]. Group 4: Fund Issuance and Research Activity - The issuance of public funds accelerated in January, with a significant number of FOFs focusing on themes like technological innovation and high-end manufacturing, reflecting market interest in economic transformation opportunities [6][7]. - A total of 156 public fund institutions participated in A-share research activities in January, covering 486 stocks across 30 first-level industries, indicating high research engagement [7].

Group 1 - The core point of the article highlights that Jingzhida (精智达) received the highest number of institutional research visits among listed companies, with 170 institutions conducting research during the last working week of January [1][2] - Jingzhida signed a significant sales contract worth 1.311 billion yuan (including tax) for semiconductor testing equipment, which has garnered considerable market attention [1][3] - The order is seen as a strong validation of the company's long-term investments and its solid market position, especially amid tight delivery schedules from international suppliers [3] Group 2 - In January, over 600 listed companies disclosed records of institutional investor research, with Dajin Heavy Industry (大金重工) receiving the most visits at 209 institutions [3][4] - The electronic and mechanical equipment sectors have shown high levels of interest from institutional investors, with these industries leading in the number of research visits [5] - The overall trend indicates a sustained enthusiasm for institutional research in the machinery and computer sectors, with a notable focus on electronic and mechanical equipment industries [5]

行 机械设备 2026 年 01 月 31 日 业 研 究 机械设备 超声脑机接口启新篇，中国方案破解脑病治疗困局 投资要点： "十五五"重点赛道，脑机接口市场规模有望快速增长 根据 precedence research，2024 年全球脑机接口市场规模约为 26.2 亿美元，预计 2025 年将达到 29.4 亿美元，到 2034 年有望增长至 124 亿美元，十年间复合年增长率为 17.35%；据工信微报，2024 年中国脑 机接口市场规模为 32.0 亿元，预计到 2028 年将达 61.4 亿元。《中共 中央关于制定国民经济和社会发展第十五个五年规划的建议》提出前 瞻布局未来产业，推动脑机接口等成为新的经济增长点。这些产业蓄 势发力，未来 10 年将再造一个中国高技术产业。 建议关注 岩山科技、汉威科技、三博脑科、创新医疗、东方中科、翔宇医 疗、熵基科技、诚益通、伟思医疗、麦澜德、爱朋医疗、倍益康等。 风险提示 证 市场竞争加剧、政策支持力度不及预期、技术研发及新产品开发 不利、脑机产品造成病患受伤等风险 技术突破创新，超声精准打开血脑屏障 行 业 定 期 报 告 近日，复旦大学联合华山医院在国家重 ...

行 机械设备 2026 年 01 月 31 日 业 研 究 机械设备 超声脑机接口启新篇，中国方案破解脑病治疗困局 投资要点： 技术突破创新，超声精准打开血脑屏障 行 业 定 期 报 告 近日，复旦大学联合华山医院在国家重点研发计划项目启动会上， 发布国内首例采用自主研制超声诊疗一体化装置"UltraBrainPad"的临 床试验成果。该半侵入式技术为全球第三种方案，通过手持式探头结 合 AI 图像识别，3 分钟即可打开胶质母细胞瘤患者血脑屏障，药物浓 度平均提升 8 倍，6 小时后屏障自动关闭，操作便捷、成本可控且安全 性优于国际水平，成功破解传统技术感染风险高、精度不足等难题。 赛道拓展赋能，惠及多种脑病治疗场景 作为国家重点研发计划项目，该技术已启动复发胶质母细胞瘤临 床研究，未来将打造超声脑机接口新赛道。除脑肿瘤药物治疗外，其 科研成果还将向神经调控、脑机融合方向转化，有望为阿尔兹海默病、 头痛、失眠等多种脑病提供全新治疗路径，凭借基层可及的优势，让 更多患者受益于这一"中国方案"。 岩山科技、汉威科技、三博脑科、创新医疗、东方中科、翔宇医 疗、熵基科技、诚益通、伟思医疗、麦澜德、爱朋医疗、倍益康等。 ...

证券代码：300753 证券简称：爱朋医疗 公告编号：2026-003 江苏爱朋医疗科技股份有限公司 2025年度业绩预告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 一、本期业绩预计情况 1、业绩预告期间：2025年1月1日至2025年12月31日 2、业绩预告情况：预计净利润为负值 （1）以区间数进行业绩预告的 三、业绩变动原因说明 1、公司归属于上市公司股东的净利润预计亏损，主要系公司主营疼痛管理业务和鼻腔 及上气道管理业务营业收入未达预期。（1）疼痛管理业务方面，2025年是输注泵集中带量 采购政策推进的第一个完整年度，公司输注泵系列产品占疼痛管理业务比重较大，受集采政 策切换过渡期及市场竞争加剧等因素影响，销量较上年同期有所下滑；同时产品终端价格和 出厂价格同比下降，对公司营业收入及净利润产生影响。（2）鼻腔及上气道管理业务方面， 报告期内鼻腔护理系列产品的临床业务开发和准入周期延长，院内收费落地和管理进程慢于 预期；同时，药店零售渠道开发难度加大，产品价格竞争进一步加剧，对公司鼻腔护理产品 的销售带来不利影响。 2、为培育发展新动能、提高公司核 ...

Group 1 - The medical device sector increased by 0.19% on January 29, with Sanyou Medical leading the gains [1] - The Shanghai Composite Index closed at 4157.98, up 0.16%, while the Shenzhen Component Index closed at 14300.08, down 0.3% [1] - Key stocks in the medical device sector showed varied performance, with Sanyou Medical rising by 5.12% to a closing price of 22.60 [1] Group 2 - Major stocks that declined included Daan Gene, which fell by 9.96% to a closing price of 6.87, and Cap Bio, down 9.88% to 7.94 [2] - The medical device sector experienced a net outflow of 376 million yuan from institutional investors, while retail investors saw a net inflow of 201 million yuan [2][3] - Notable net inflows from retail investors were observed in stocks like Lepu Medical, which had a net inflow of 42.29 million yuan [3]

全球脑机接口玩家奋楫争先，产业化落地谱写投资蓝图 20260128 摘要 创新药领域，减肥、小核酸及 2L 疗法值得关注。减肥和 IO 赛道市场规 模达千亿美元级别，具弹性机会。小核酸赛道也因高景气度备受关注。 全年维度来看，医药板块值得重点关注。 脑机接口商业化处于起步阶段，是 2026 年投资主线。植入式临床进展 迅速，心伟医疗、爱鹏医疗和乐普医疗安全性具优势。非侵入式方面， 翔宇、迈兰德、创新医疗和诚益通等公司靠前。 政策支持对脑机接口行业发展起到重要引领作用，2025 年推出发展目 标与产业规划蓝图，确立收费项目立项，提高公立医院购买积极性，为 未来纳入医保铺平道路。 脑机接口产业链核心技术壁垒集中于中上游，包括硬件（电极、芯片）、 手术机器人及算法处理等。国产替代进程加速，美好医疗率先卡位上游 并开始代工侵入型电极。 Neuralink 需定制 ASIC 芯片，因通用芯片无法在处理上千通道信号的 同时控制功耗。其关键部分是模拟前端，需实现微弱神经信号的放大、 滤波和数字化。 Q&A 目前医药板块的投资机会主要集中在哪些方向？ 当前医药板块的投资机会主要集中在创新药及其相关产业链上。尤其是一些龙 头企 ...